Agile Therapeutics, Inc.,
(NASDAQ: AGRX), a women's health specialty pharmaceutical company
focused on the development and commercialization of new prescription
contraceptive products, today announced that patent U.S. 8,747,888 ('888
Patent), was issued by the U.S. Patent and Trademark Office on June 10,
2014. The patent is a continuation of its prior patent US 8,246,978 and
is intended to provide additional patent protection covering its
contraceptive patch, Twirla(TM) ethinyl estradiol and levonorgestrel
"The granting of this patent further strengthens the patent protection
of our proprietary Skinfusion(R) transdermal technology used in our
contraceptive patch, Twirla currently in Phase 3 clinical development,"
said Al Altomari, Chief Executive Officer and President of Agile. "The
issuance of this patent demonstrates our commitment to protecting our
intellectual property in our proprietary transdermal technology and is
expected to provide protection into 2028."
Agile will submit the '888 Patent to the FDA in addition to previously
submitted patent information on five other issued patents on its
propriety Skinfusion transdermal technology. If the Company's New Drug
Application for Twirla is approved, the Company intends the '888 Patent
to be the sixth patent that will be listed in the FDA Orange Book. The
Company has multiple additional patent applications on file, all
relating to further advances in Skinfusion transdermal delivery system.
See more from Benzinga
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.